SILO Pharma (SILO Pharma) Retained Earnings : $-10.87 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. SILO Pharma's retained earnings for the quarter that ended in Dec. 2023 was $-10.87 Mil.

SILO Pharma's quarterly retained earnings declined from Jun. 2023 ($-9.09 Mil) to Sep. 2023 ($-9.75 Mil) and declined from Sep. 2023 ($-9.75 Mil) to Dec. 2023 ($-10.87 Mil).

SILO Pharma's annual retained earnings declined from Dec. 2021 ($-3.26 Mil) to Dec. 2022 ($-7.17 Mil) and declined from Dec. 2022 ($-7.17 Mil) to Dec. 2023 ($-10.87 Mil).

SILO Pharma Retained Earnings Historical Data

The historical data trend for SILO Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SILO Pharma Retained Earnings Chart

SILO Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-2.66

-5.76

-3.26

-7.17

-10.87

SILO Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-7.17	-8.08	-9.09	-9.75	-10.87

SILO Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

SILO Pharma (NAS:SILO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

SILO Pharma (SILO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632

Website

https://www.silopharma.com

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.

Executives

Eric Weisblum	director, officer: President and CCO	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz	director	560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman	officer: Chief Financial Officer	1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller	director
Joel Alan Stone,	director	1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps	director	C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand	director, officer: Chairman and CEO	10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd	10 percent owner	P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats	officer: VP of Business Development	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis	director, officer: CFO	72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg	director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY	72 POND ROAD, WOODBURY NY 11797